Lupin’s US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) has received final approval for its Desoximetasone Ointment USP, 0.25% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25%. Topicort had US sales of $14.4 million, as per IMS MAT September 2016.
Lupin’s Desoximetasone Ointment USP, 0.25% is the AB rated generic equivalent of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
